FDA lukewarm to new safety warning system

Despite the FDA's current push for better drug safety data, the agency has responded with only lukewarm enthusiasm to Medicare's proposal that it track the drug reactions of beneficiaries. Medicare chief Mark McClellan believes he can combine billing and healthcare data that will spot drug reaction trends. That kind of data, he believes, would have gone a long way to discovering the safety problems now linked to Cox-2 inhibitors. The FDA, though, appeared noncommittal about the proposal, saying it was too early to decide for or against the initiative.

- read this story from the Los Angeles Times for more

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.